Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

• Main Authors: Felix Huth (Author), Hilmar Schiller (Author), Yi Jin (Author), Birk Poller (Author), Carole Schuhler (Author), Wendy Weis (Author), Ralph Woessner (Author), Anton Drollmann (Author), Peter End (Author)
• Format: Book
• Published: Wiley, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Remibrutinib, a novel oral Bruton's Tyrosine Kinase inhibitor (BTKi) is highly selective for BTK, potentially mitigating the side effects of other BTKis. Enzyme phenotyping identified CYP3A4 to be the predominant elimination pathway of remibrutinib. The impact of concomitant treatment...